Elixir hot on Abbott’s tail in bioresorbable stent race
This article was originally published in Clinica
Executive Summary
Abbott’s monopoly of the fully bioresorbable stent market has ended, after Elixir Medical – a much smaller player compared to the Illinois company – received CE mark approval for its DESolve novolimus-eluting stent.